Bladder cancer duo: BCG plus immunotherapy drug shows promise in early trial

NCT ID NCT05943106

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard BCG treatment can safely control high-risk non-muscle-invasive bladder cancer. About 100 adults who have never received BCG before will get both treatments for up to a year. The main goal is to check for serious side effects, while also seeing how well the combination works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCG (a weakened germ given into the bladder) plus durvalumab (an immunotherapy drug given by IV)
What this could lead to: If it works, this combination could offer a more effective way to control high-risk bladder cancer and reduce the chance of it coming back.
What could go wrong: This is an early-phase, single-arm study with no placebo group, so results may not prove the combination is better than standard care. Side effects from both drugs could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms superficial urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Show contact details

Locations

Research Site

Phoenix, Arizona, 85054, United States
Research Site

Little Rock, Arkansas, 72211, United States
Research Site

San Diego, California, 92123, United States
Research Site

Lakewood, Colorado, 80228, United States
Research Site

Hialeah, Florida, 33016, United States
Research Site

Jacksonville, Florida, 32209, United States
Research Site

Greenwood, Indiana, 46143, United States
Research Site

Wichita, Kansas, 67226, United States
Research Site

Baltimore, Maryland, 21203, United States
Research Site

Hanover, Maryland, 21076, United States
Research Site

Royal Oak, Michigan, 48073, United States
Research Site

Troy, Michigan, 48084, United States
Research Site

Syracuse, New York, 13210, United States
Research Site

Cincinnati, Ohio, 45212, United States
Research Site

Bala-Cynwyd, Pennsylvania, 19004-1017, United States
Research Site

Myrtle Beach, South Carolina, 29572, United States
Research Site

Nashville, Tennessee, 37209, United States
Research Site

Austin, Texas, 78759, United States
Research Site

Spokane, Washington, 99202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.